UNITY Biotechnology Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema Apr 24, 2023 at 8:00 AM EDT Click here for webcast Supporting Materials UBX1325 Phase 2 BEHOLD 48-week Data Investor Call Presentation 23.1 MB